{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087035","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.364536+00:00","generated_at":"2026-05-31T11:05:09.771922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Replimune Q1 FY2025: $53.8M net loss, $469.1M cash; RP1 BLA on track for 2H 2024","bullets":["Net loss $53.8M for Q1 ended June 30, 2024, up from $49.6M YoY; R&D expenses $43.0M versus $40.4M.","Cash, cash equivalents and short-term investments $469.1M; $96.7M net PIPE financing supports operations into 2H 2026.","Pre-BLA meeting with FDA scheduled for September 2024; RP1 BLA submission planned for 2H 2024.","First patient enrollment in Phase 3 confirmatory IGNYTE-3 trial for RP1 in anti-PD1 failed melanoma expected Q3 2024.","Protocol finalized for registration-directed study of RP2 in uveal melanoma; Phase 2 HCC trial first patient expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087035","json":"https://secwatch.observer/filing/0001104659-24-087035.json","markdown":"https://secwatch.observer/filing/0001104659-24-087035.md","text":"https://secwatch.observer/filing/0001104659-24-087035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924087035/0001104659-24-087035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924087035/tm2421132d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:05:09.771922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}